SAN ANTONIO, Dec. 15 /PRNewswire/ -- An interim analysis of the XCALIBr (Xeloda in Combination with Avastin as First-Line Treatment for HER2-Negative Metastatic Breast Cancer) trial suggested that first-line therapy with oral Xeloda® (capecitabine) in combination with Avastin® (bevacizumab) may offer clinical benefit in metastatic breast cancer patients who have no prior history of treatment. These data were presented at the 29th Annual San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.
